Keyword Index to Volume 11

Size: px

Start display at page:

Download "Keyword Index to Volume 11"

Bridget Long
5 years ago
Views:

1 Journal of Clinical Lipidology (2017) 11, e7 e12 Keyword Index to Volume 11 A 7a-hydroxycholesterol, 1032 ABCA1, 242 ABCG5/G8, 1432 Acid sphingomyelinase, 694 Acute ischemic stroke, 915 Acute pancreatitis, 1091, 1383 Adherence, 485, 986 Adipose tissue, 34 Adolescents, 575 Adrenal steroidogenesis, 733 Adrenal venous sampling, 733 Advanced chronic kidney disease, 422 Advanced Lipid Technologies, 394 Adverse effects, 485 Age, 80, 1161 Agena iplex assay, 386 Agena s MassARRAY, 386 AIDS, 4 Alcohol, 1383 Alirocumab, 195, 880, 986, 1485 Altitude, 1212 Aminotransferases, 915 Androgens, 469 Angiopoietin-like protein 3, 543 ANGPTL3 gene, 1234 ANRIL, 406 Anti-diabetic drug, 1145 Antiretroviral drugs, 4 Aorta, 1372 Apheresis, 282 APOA5, 1329 ApoA-I, 712, 1168 ApoB, 34, 1065, 1181 APOB, 1338, 524 APOB gene, 1234 ApoCII, 1407 Apolipoprotein, 1347 Apolipoprotein A-I, 215, 242, 469 Apolipoprotein B, 442, 646 Apolipoprotein C-III, 224, 495 Apolipoprotein E, 12 Apolipoprotein J, 178 Apolipoprotein-CII, 1407 Apolipoproteins, 362 Apolipoproteins AI and B, 369 Arachidonic acid, 1082 Argentina, 524 ARH, 287 Arterial stiffness, 185, 901, 1023, 1354 ASCVD, 1065 Atherogenic dyslipidemia, 551, 1201 Atherosclerosis, 12, 160, 167, 377, 682, 1126, 1181, 1223, 1361, 1372 Atherosclerotic cardiovascular disease, 1284 Athlete, 1134 a-tocopherol, 515 Atorvastatin, 657 Autoantibodies, 1480 Autosomal dominant, 12 Autosomal recessive hypercholesterolemia, 287 B b 3 -AR, 1168 Bariatric surgery, 495 Bioavailability, 394 Biologics, 749 Biomarker, 178 Biomarkers, 682 Body mass index, 362, 1354 Breast enlargement, 763 Brown adipose tissue, 920 C Calcium score, 704 Carbohydrate, 338 Cardiac death, 1152 Cardiac magnetic resonance imaging, 1421 Cardiometabolic risk, 1007 Cardiovascular, 61, 204, 450, 1338 Cardiovascular disease, 80, 94, 119, 260, 289, 338, 406, 485, 495, 524, 562, 602, 617, 674, 725, 749, 1013, 1055, 1161, 1201, 1441 Cardiovascular disease prevention, 524, 704 Cardiovascular disease risk, 1223 Cardiovascular disease risk factor, 348 Cardiovascular health, 147 Cardiovascular risk, 929, 1177, 1243 Cardiovascular risk factors, 1055 Cardiovascular risks, 915 Carotid, 1372 Carotid arteries, 1023 Carotid intima-media thickness, 442 Carotid plaque, 1181 Cascade screening, 160 Cascade screening program, /$ - see front matter Ó 2017 National Lipid Association. All rights reserved.

2 e8 Journal of Clinical Lipidology, Vol 11, No 6, December 2017 Caveolin-3, 1280 Cellular adhesion, 955 CETP, 938 Childhood/adult-onset LALD, 167 Children, 575 Children non-alcoholic fatty liver disease, 167 Chinese, 386 Cholestasis, 110 Cholestatic liver disease, 282 Cholesterol, 46, 94, 160, 195, 234, 485, 524, 532, 587, 667, 846, 920, 972, 998, 1055, 1126, 1177, 1393 Cholesterol absorption, 1432 Cholesterol burden, 704 Cholesterol efflux, 242, 1347 Cholesterol ester storage disease, 167, 477 Cholesteryl ester transfer protein (CETP), 1318 Chronic disorder, 147 Chronic kidney disease, 87 Chylomicronemia, 1091 Chylomicronemia syndrome, 294 Chylomicrons, 964 Chylous ascites, 1091 Cigarette smoke, 638 Cinnamon, 1393 Circulating angiogenic cells, 694 Clinical trial, 1338 Clusterin, 178 Cohort, 377 Cold exposure, 920 Combined fat and physical load, 369 Community-based cohort study, 348 Coronary artery calcification, 432, 704 Coronary artery calcium, 1007 Coronary artery disease, 624, 682, 1192, 1309 Coronary atherosclerosis, 413 Coronary heart disease, 646, 1177 Coronary heart disease (CHD), 369 Cost-effectiveness, 260 Cotinine, 638 Creatine kinase, 1280 Cushing syndrome, 562 CVD, 316 D Dairy products, 136 Dapagliflozin, 450 Density, 1458 DHA, 1152 Diabetes, 485, 712, 1126 Diabetes mellitus, 1201, 1383 Diabetic retinopathy, 694 Dietary cholesterol, 432 Discontinuation, 204 Discordance, 667 Discordance analysis, 442 Disease phenocopy, 1480 Docosahexaenoic acid, 250, 394, 739, 1152 Docosapentaenoic acid, 102, 1361 Double-blind, 195 Dual-energy X-ray absorptiometry, 1354 Dyslipidemia, 110, 167, 242, 338, 362, 442, 450, 495, 562, 638, 858, 872, 880, 891, 908, 929, 1023, 1101, 1212, 1223, 1415 Dyslipidemias, 532 E egfr, 87 Eicosapentaenoic acid, 102, 250, 394, 739, 1152, 1361 Electromyography test, 1280 Electronic health records, 1013 Embryo, 1318 Endothelial activation, 955 Endothelial cells, 964 Endothelial dysfunction, 901, 1415 Environment, 1212 EPA, 1152 Epicardial fat, 1421 Epidemiology, 94, 119, 250, 377, 955 Epigenetics, 532 Estrogen, 297 Ethnicity, 348 Evolocumab, 287, 880 Exercise, 1134 Extended-release niacin, 1201 Ezetimibe, 289, 929 F Familial chylomicronemia, 1329 Familial combined hypolipidemia, 1234 Familial defective apolipoprotein B-100, 1471 Familial dysbetalipoproteinemia, 12 Familial hypercholesterolemia, 80, 147, 160, 260, 386, 406, 477, 507, 524, 575, 674, 682, 704, 725, 858, 880, 891, 1013, 1055, 1161, 1284, 1448, 1471 Familial hypobetalipoproteinemia, 1234 Family history, 1415 Fat, 338 Fatty acids, 185 Fatty liver index, 551 Femoral, 1372 Fibrates, 289, 872 Fish oil, 1152, 1289 Food and drug administration, 1309 Food-effect, 394 G Gas chromatography-mass spectrometry, 515 GCKR, 938 Gender, 80, 1161 Gene, 357 Gene expression, 532 Gene mutation, 515 Gene regulation, 532 Genes, 12 Genetic analysis, 1475 Genetic hepatic steatosis, 167 Genetic hypercholesterolemia, 1432 Genetic risk score, 725

3 Journal of Clinical Lipidology, Vol 11, No 6, December 2017 e9 Genetic variants, 524 Genetics, 294, 532, 1338 Genotyping, 386 Gestational diabetes, 459 Glucocorticoids, 469 Glucose, 46 Glycemic control, 459 Growth velocity, 562 Guidelines, 872 H Half-life, 972 HDL, 46, 495, 908, 955, 1192 HDL cholesterol, 1234 HDL function, 712, 1243 HDL metabolism, 242 HDL mimetic, 858 HDL-C, 80, 289, 725, 1073, 1161 HDL-Cholesterol, 338 Health care costs, 70 Heart disease, 1309 Heart failure, 178, 1421 HeFH, 195 Heparan sulfate proteoglycans, 12 Hepatic enzyme elevation, 567 Hepatic steatosis, 1234 Heterozygous familial hypercholesterolemia, 294, 413 Heterozygous N291S mutation, 515 High CV risk, 70 High-density lipoprotein, 119, 920 High-density lipoprotein cholesterol, 215, 234, 646, 938, 945 High-density lipoprotein particles, 733 High-density lipoproteins, 469, 1043 HIV, 4, 61 HoFH, 602 HOMA-IR, 46 Homozygous autosomal dominant hypercholesterolemia, 507 Homozygous familial hypercholesterolemia, 301, 602, 1284 Hydrophilic statins, 624 Hydroxymethylglutaryl-CoA reductase inhibitors, 972 Hyperalphalipoproteinemia, 1192 Hypercholesterolemia, 167, 880, 986, 1280, 1338, 1485 Hyperlipidemia, 282, 567, 1091 Hyperlipoproteinemia, 357 Hypertension, 80, 485, 638, 1161 Hypertension risk, 998 Hypertriglyceridemia, 102, 272, 297, 357, 739, 872, 901, 1007, 1329, 1361, 1480 Hypobetalipoproteinemia, 1101 Hypocholesterolemia, 1101 Hypothyroidism, 1347 I Immune activation, 61 Immunodeficiency, 4 Immunosuppression, 1480 IMT, 1181 In vitro fertilization, 297 Infectious diseases, 4 Inflammation, 61, 215, 657, 712, 1043 Inherited HDL deficiency, 1475 Injection, 986 Injection site reaction, 674 InsLEU mutation, 55 Insulin, 46, 1126 Insulin resistance, 34, 167, 348, 495, 763, 1007, 1257 Insulin secretion, 34 Insulin sensitivity, 515 Insulin-like growth factor I, 1032 Integrated health system, 70 Intima-media thickness, 167 Intravascular lipolysis, 964 Intravascular ultrasound, 413 Ion torrent PGM sequencing, 272 Isoflavone, 46 K Kefir, 136 Kidney disease, 1475 Korean, 338 L LCAT, 242 LCAT deficiency, 1475 LDL, 46, 532, 908, 972 LDL cholesterol, 87, 575 LDL-C, 70, 195, 406, 602, 725, 1065, 1448 LDL-cholesterol, 858 LDLR, 1338 LDLR gene, 524 LDLRAP1, 287 Lead, 234 Left ventricular diastolic dysfunction, 657 Leptin, 543 Lifestyle modification, 1441 Linoleic acid, 1082 LIPA, 477 LIPA gene, 567 LIPC, 938 LIPC and APOB genes, 1329 Lipid, 1347 Lipid concentrations, 459 Lipid disorders, 4 Lipid levels, 1055, 1243 Lipid lowering, 195, 301 Lipid mediators, 1289 Lipid metabolism, 1243 Lipid modulators, 1480 Lipid profile, 119 Lipid profiles, 1393 Lipid therapy, 195 Lipid treatment guidelines, 880 Lipid-lowering therapy, 674 Lipidomics, 1192 Lipids, 12, 24, 945, 964, 972, 1065, 1177 Lipids and lipoprotein metabolism, 920 Lipodystrophy, 543

4 e10 Journal of Clinical Lipidology, Vol 11, No 6, December 2017 Lipophilic statins, 624 Lipoprotein, 282, 328, 587, 846, 1257, 1318 Lipoprotein apheresis, 858 Lipoprotein lipase, 357, 1383, 1480 Lipoprotein lipase deficiency, 515, 757 Lipoprotein metabolism, 316, 495 Lipoprotein X, 1475 Lipoprotein(a), 507, 667, 749, 1177 Lipoproteins, 46, 136, 551, 858, 908, 955, 1023, 1181, 1243, 1309 Lipoprotein-X, 110 Lipoprotein-X disease, 282 Liver steatosis, 1101 Liver transplantation, 282 LMF1 gene, 272 Lomitapide, 301 Long noncoding RNAs, 617 Low cholesterol syndromes, 1234 Low-density lipoprotein, 224, 667 Low-density lipoprotein cholesterol, 234, 432, 929, 945, 986 Low-density lipoprotein particles, 733 Low-density lipoprotein pattern, 1458 Lp(a), 1161, 1177 Lp(a) hyperlipoproteinemia, 858 LPL, 357 LPL, 1329 LP-PLA2, 328 Lung cancer, 1073 Lupus, 1480 Lysosomal acid lipase deficiency, 477, 567 M Macrophage, 110 Macrothrombopenia, 1095 Mass spectrometry, 224, 1407 Maximally tolerated statin, 195 Mediterranean diet, 1372 MEGA study, 998 Menopause, 316 Meta-analysis, 1073, 1152 Metabolic disorders, 587, 846 Metabolic syndrome, 469, 562, 638, 901, 1201 Metabolism, 224, 587, 846 Metabolomics, 1257 Metallothionein, 234 microrna, 532 Milk, 136 Mipomersen, 301 Mixed meal, 377 Molecular diagnosis, 160, 1475 Monoclonal antibody, 1448 Monocytes, 1361 Monounsaturated fatty acids, 126 Mortality, 126, 204, 422, 945, 1082, 1458 MTP inhibition, 858 Multiple symmetric lipomatosis, 763 Muscle symptoms, 1145 Muscular symptoms, 204 Musculoskeletal symptoms, 24 Mutation, 357 Mutations, 524 Myalgia, 24 Myocardial fibrosis, 1421 Myocardial infarction, 215, 1458 Myopathy, 24, 1134 N n-3 polyunsaturated fatty acids, 1289, 1361 Nervonic acid, 126 Niacin, 1309 Nicotinic acid, 1309 NMR, 1181 Nonadherence, 204, 986 Nonalcoholic fatty liver disease, 551, 915, 1101 Noncholesterol sterols, 1432 Non-enzymatic glycation, 712 Non-HDL-C, 1065 Non HDL-cholesterol, 442 Nonsense mutation, 272 Normal serum amylase and lipase levels, 1091 Nuclear magnetic resonance, 955 Nuclear magnetic resonance spectroscopy, 551 Nutraceuticals, 1393 Nutrition, 126, 1082 O Obesity, 136, 495, 1383 Oleic acid, 126 Omega-3 carboxylic acids, 739 Omega-3 fatty acid, 459 Omega-3 fatty acids, 102, 250, 394, 872, 1152 Omega-3 index, 1289 Omega-6 fatty acids, 250, 1082 Outcome, 915 Ovarian, 316 Overweight, 136, 185 Oxidative status, 1043 Oxidized LDL, 61, 110 Oxysterols, 1032 P 9p21.3, 406 Pancreatitis, 297, 1480 Panel-based NGS sequencing, 272 Paradox, 1458 Paraoxonase, 1043 Paraoxonase-1 activity, 1347 Patient perspective, 485 Patients, 763 PCSK9, 55, 87, 195, 287, 1065, 1101, 1338, 1448 PCSK9 inhibition, 858 PCSK9 inhibitor, 1471, 1485 PCSK9 inhibitors, 287, 294, 602, 674, 880, 891 Pediatrics, 1023 Peripheral artery disease, 1289 Peritoneal dialysis, 657, 945 Persistence, 485 Pharmacokinetic interaction, 739

5 Journal of Clinical Lipidology, Vol 11, No 6, December 2017 Phospholipids, 1192 Physical activity, 1268 Physical work capacity, 369 Phytosterols, 1095 Placebo-controlled, 195 Plaques, 1372 Plasminogen activator inhibitor-1, 442 PNPLA3, 1101 Polymorphisms, 532, 938 Population study, 362, 1055 Postprandial, 377 Postprandial metabolism, 1268 Postprandial triglycerides, 1415 Practice patterns, 891 Pravastatin, 998 Prebeta-1 HDL, 908 Prebeta-HDL, 242 Prediabetes, 1007, 1415 Pregnancy, 297, 938, 1091 Premature coronary artery disease, 1407 Premenopause, 136 Prevention, 94, 998, 1177, 1257 Primary prevention, 1055, 1441 Progestin, 316 Prognosis, 178 Proprotein convertase subtilisin kexin type 9, 102 Proprotein convertase subtilisin/kexin type 9, 413, 667, 1101 Proprotein convertase subtilisin/kexin type 9 inhibitor, 986 Prospective cohort study, 250 Proteomics, 682 Pseudoacidosis, 757 Psoriasis, 1243 Public health, 524 PUFA, 185 Pulse wave velocity, 1354 PWV, 185 R R46L mutation, 55 Randomized controlled trial, 136, 998 Reference values, 1055 Regulation of gene expression, 1168 Remnant accumulation, 34 Remnant lipoprotein metabolism, 12 Residual cardiovascular risk, 1177 Resolution of inflammation, 1289 Revascularization, 694 Reverse cholesterol transport, 908 Rhabdomyolysis, 24 Rheumatoid arthritis, 749, 1043 Rippling muscle disease, 1280 Risk estimation, 1441 Risk factors, 955, 1082, 1223 Risk prediction, 80, 1257 Risk stratification, 725, 1161 Rosuvastatin, 739 Rurality, 1212 S 24S-hydroxycholesterol, 1032 Safety, 1448 Scavenger receptor, 110 Screening, 575 Sebelipase alfa, 567 Secondhand smoke, 638 Sedentary behaviour, 1268 Sedentary lifestyle, 1268 Sensitivity, 55 Severe hypertriglyceridemia, 757, 1383 SGLT2 inhibitors, 450 Sialylation, 224 Side effects, 674 Simvastatin, 739 Single nucleotide polymorphism, 234 Sitosterol, 1095 Sitosterolemia, 1095 Size, 1458 Sj ogren s, 1480 Small dense LDL cholesterol, 348 Small for gestational age, 1318 Smoking, 80, 638, 1161 SNP, 725 Soy, 46 Specialized pro-resolving mediators, 1289 Specificity, 55 Splicing, 357 Statin, 61, 204, 422, 646, 929 Statin intolerance, 24, 70, 880 Statin myalgia, 1145 Statin therapy, 1441 Statin treatment, 908 Statins, 24, 94, 485, 891, 1134, 1223 Stomatocytosis, 1095 Stroke, 422 ST-segment elevation myocardial infarction, 1407 Subclinical, 328 Subclinical atherosclerosis, 432 Supplementation, 459 Survey, 485 Systematic review, 712 e11 T Targeted next-generation sequencing, 1329 TC, 1073 Tendon xanthomata, 1095 TG, 725, 1073 Tissue Doppler imaging, 657 TM6SF2, 1101 Tocilizumab, 749 Tofacitinib, 1243 Tolerability, 1448 Total cholesterol, 945 Transition to adult care, 147 Treatment, 301 Triglyceride, 646, 938, 945 Triglyceride rich lipoproteins, 294 Triglyceride-rich lipoprotein, 495 Triglyceride-rich lipoproteins, 1043 Triglycerides, 87, 102, 119, 234, 338, 377, 587, 846, 908, 964, 1043, 1126, 1393 Truncal obesity, 1354 Type 2 diabetes mellitus, 362

6 e12 Journal of Clinical Lipidology, Vol 11, No 6, December 2017 Type I hyperlipoproteinemia, 757 Type II diabetes, 617, 1257 Type II diabetes mellitus, 450 U Uniparental disomy, 757 Unstable angina, 215 Urbanization, 1212 V Vitamin D, 459 von Willebrand factor, 442 X Xanthoma, 110 Y Young adult, 147 Youth, 562 Z Zebrafish, 1318 ZPR1, 938

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant